Coloma Jason V 4

What Happened
Jason V. Coloma, CEO of Maze Therapeutics (MAZE), sold a total of 6,643 shares on June 1, 2026 in two open-market/private-sale transactions, generating proceeds of approximately $174,048. The filings report 6,090 shares at $26.20 (≈ $159,537) and 553 shares at $26.24 (≈ $14,511). These sales were effected pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: June 1, 2026 (Form 4 filed June 3, 2026) — filing appears timely.
• Transaction type: Sale (Code S) — open market or private sale.
• Share amounts & reported prices: 6,090 @ $26.20; 553 @ $26.24; total 6,643 shares for ≈ $174,048.
• Price details: Filings note weighted-average pricing and multiple executions with prices in ranges reported ($26.00–$26.545 and $26.00–$26.50); the filer can provide a full breakdown on request (see footnotes).
• Holdings: The filing does not state the reporter’s total MAZE shares owned after these transactions.
• Ownership/beneficial interest: Some of the securities are held directly by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Mr. Coloma and his spouse serve as co-trustees.
• Plan: Transactions were made under a 10b5-1 trading plan adopted Feb 6, 2026 (footnote).
• Timeliness: No late filing flag reported.

Context
These are sales (not purchases), commonly used for liquidity or portfolio management; the presence of a 10b5-1 plan indicates the trades were pre-authorized and executed according to that plan. The trusts named as holders mean the reported sales relate to trust-held shares rather than directly to a personal brokerage account. No inference should be drawn about the company’s prospects from routine, plan-driven insider sales.